Multiple Sclerosis Clinical Trial
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
Summary
Primary Objective:
To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic acid (DNA) analysis as part of a global biomarker project assessing pre-identified candidate single nucleotide polymorphisms (SNPs) associated to the development of ITP after LEMTRADA treatment in RMS participants.
Full Description
One to 70 days, as screening and inclusion visit(s) were performed the same day or on separate days with a maximum timeframe of 30 days apart. One visit was required for blood draw. However, if a second visit occured, it took place within 40 days of the first visit.
Eligibility Criteria
Inclusion criteria :
Male and female adult participants who had been treated with LEMTRADA, with development of ITP subsequent to treatment. Participants does not need to be currently on LEMTRADA treatment.
Participants who had signed the study ICF.
Exclusion criteria:
- Not applicable
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Los Angeles California, 90094, United States
How clear is this clinincal trial information?
